# Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients

> **NCT01830491** · PHASE4 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 162 (actual)

## Conditions studied

- Coronary Artery Disease (CAD)

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** aspirin 100mg

## Key facts

- **NCT ID:** NCT01830491
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-08
- **Final completion:** 2009-12
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01830491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01830491, "Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01830491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*